Recently, a new approach for the treatment of CKD has been proposed—the use of a combination of the neprilysin inhibitor (sacubitril), which inhibits the cleavage of natriuretic peptides, and the AT1 antagonist valsartan (ARNI—angiotensin receptor AT1 and neprilysin inhibition). The gene discussed is MME; the disease is chronic kidney disease.